450 related articles for article (PubMed ID: 28646014)
1. The Impact of
Roach PJ; Francis R; Emmett L; Hsiao E; Kneebone A; Hruby G; Eade T; Nguyen QA; Thompson BD; Cusick T; McCarthy M; Tang C; Ho B; Stricker PD; Scott AM
J Nucl Med; 2018 Jan; 59(1):82-88. PubMed ID: 28646014
[No Abstract] [Full Text] [Related]
2. Impact of
Sonni I; Eiber M; Fendler WP; Alano RM; Vangala SS; Kishan AU; Nickols N; Rettig MB; Reiter RE; Czernin J; Calais J
J Nucl Med; 2020 Aug; 61(8):1153-1160. PubMed ID: 31924715
[TBL] [Abstract][Full Text] [Related]
3. [
Hirmas N; Al-Ibraheem A; Herrmann K; Alsharif A; Muhsin H; Khader J; Al-Daghmin A; Salah S
Mol Imaging Biol; 2019 Jun; 21(3):574-581. PubMed ID: 30215174
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
6.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
7. Impact of
Calais J; Fendler WP; Eiber M; Gartmann J; Chu FI; Nickols NG; Reiter RE; Rettig MB; Marks LS; Ahlering TE; Huynh LM; Slavik R; Gupta P; Quon A; Allen-Auerbach MS; Czernin J; Herrmann K
J Nucl Med; 2018 Mar; 59(3):434-441. PubMed ID: 29242398
[TBL] [Abstract][Full Text] [Related]
8. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
9. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
10. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
11. Impact of
Schmidt-Hegemann NS; Eze C; Li M; Rogowski P; Schaefer C; Stief C; Buchner A; Zamboglou C; Fendler WP; Ganswindt U; Cyran C; Bartenstein P; Belka C; Ilhan H
J Nucl Med; 2019 Jul; 60(7):963-970. PubMed ID: 30552203
[No Abstract] [Full Text] [Related]
12. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
13. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
14. Impact of
Ferraro DA; Garcia Schüler HI; Muehlematter UJ; Eberli D; Müller J; Müller A; Gablinger R; Kranzbühler H; Omlin A; Kaufmann PA; Hermanns T; Burger IA
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):652-664. PubMed ID: 31802175
[TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
16. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of
Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419
[TBL] [Abstract][Full Text] [Related]
20. Impact of
Fendler WP; Ferdinandus J; Czernin J; Eiber M; Flavell RR; Behr SC; Wu IK; Lawhn-Heath C; Pampaloni MH; Reiter RE; Rettig MB; Gartmann J; Murthy V; Slavik R; Carroll PR; Herrmann K; Calais J; Hope TA
J Nucl Med; 2020 Dec; 61(12):1793-1799. PubMed ID: 32358094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
